(CercleFinance.com) – Valneva announces that the United States Department of Defense (DoD) has decided not to exercise the second annual option of the contract for the supply of its vaccine against Japanese encephalitis (JE) Ixiaro, deeming its stocks sufficient for his current needs.
The DoD, which has relied on Ixiaro since 2010 to help protect its personnel deployed to areas where JE is endemic, has nevertheless expressed interest in negotiating a new supply contract in 2023.
The French vaccine company does not anticipate any impact of this decision on its financial forecast for 2022 and will continue to deliver Ixiaro until the fourth quarter of 2022, in accordance with the terms of the first annual option.
The total minimum value of the existing supply contract was approximately $118 million, assuming exercise of the second annual option, which had a minimum value of approximately $36 million for 250,000 doses.